ENLV Valuation
Enlivex Therapeutics Ltd
$
1.560
- Overview
- Forecast
- Valuation
- Earnings
ENLV Relative Valuation
ENLV's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ENLV is overvalued; if below, it's undervalued.
Historical Valuation
Enlivex Therapeutics Ltd (ENLV) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -4.53. The fair price of Enlivex Therapeutics Ltd (ENLV) is between to according to relative valuation methord.
Relative Value
Fair Zone
-
Current Price：1.56
Fair
-2.70
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Enlivex Therapeutics Ltd. (ENLV) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.
-0.86
EV/EBIT
Enlivex Therapeutics Ltd. (ENLV) has a current EV/EBIT of -0.86. The 5-year average EV/EBIT is -2.15. The thresholds are as follows: Strongly Undervalued below -8.58, Undervalued between -8.58 and -5.37, Fairly Valued between 1.06 and -5.37, Overvalued between 1.06 and 4.27, and Strongly Overvalued above 4.27. The current Forward EV/EBIT of -0.86 falls within the Historic Trend Line -Fairly Valued range.
0.00
PS
Enlivex Therapeutics Ltd. (ENLV) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.
-2.02
P/OCF
Enlivex Therapeutics Ltd. (ENLV) has a current P/OCF of -2.02. The 5-year average P/OCF is -0.74. The thresholds are as follows: Strongly Undervalued below -3.24, Undervalued between -3.24 and -1.99, Fairly Valued between 0.51 and -1.99, Overvalued between 0.51 and 1.76, and Strongly Overvalued above 1.76. The current Forward P/OCF of -2.02 falls within the Undervalued range.
-2.02
P/FCF
Enlivex Therapeutics Ltd. (ENLV) has a current P/FCF of -2.02. The 5-year average P/FCF is -0.80. The thresholds are as follows: Strongly Undervalued below -3.56, Undervalued between -3.56 and -2.18, Fairly Valued between 0.58 and -2.18, Overvalued between 0.58 and 1.96, and Strongly Overvalued above 1.96. The current Forward P/FCF of -2.02 falls within the Historic Trend Line -Fairly Valued range.
Enlivex Therapeutics Ltd (ENLV) has a current Price-to-Book (P/B) ratio of 1.70. Compared to its 3-year average P/B ratio of 1.17 , the current P/B ratio is approximately 45.25% higher. Relative to its 5-year average P/B ratio of 1.73, the current P/B ratio is about -1.69% higher. Enlivex Therapeutics Ltd (ENLV) has a Forward Free Cash Flow (FCF) yield of approximately -37.95%. Compared to its 3-year average FCF yield of -57.30%, the current FCF yield is approximately -33.77% lower. Relative to its 5-year average FCF yield of -39.51% , the current FCF yield is about -3.93% lower.
1.82
P/B
Median3y
1.17
Median5y
1.73
-37.95
FCF Yield
Median3y
-57.30
Median5y
-39.51
Competitors Valuation Multiple
The average P/S ratio for ENLV's competitors is 0.22, providing a benchmark for relative valuation. Enlivex Therapeutics Ltd Corp (ENLV) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Performance Decomposition
1Y
3Y
5Y
Market capitalization of ENLV increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of ENLV in the past 1 year is driven by Unknown.
People Also Watch
CKX
CKX Lands Inc
11.660
USD
-0.77%
PLUR
Pluri Inc
4.860
USD
+2.53%
MXC
Mexco Energy Corp
8.200
USD
-2.73%
BNAI
Brand Engagement Network Inc
0.311
USD
-2.51%
KFFB
Kentucky First Federal Bancorp
3.100
USD
-2.33%
GFAI
Guardforce AI Co Ltd
1.210
USD
+6.61%
HUDI
Huadi International Group Co., Ltd.
1.130
USD
+2.73%
LVTX
LAVA Therapeutics NV
1.530
USD
0.00%
LRE
Lead Real Estate Co Ltd
1.580
USD
+3.27%
FAQ
Is Enlivex Therapeutics Ltd (ENLV) currently overvalued or undervalued?
Enlivex Therapeutics Ltd (ENLV) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -4.53. The fair price of Enlivex Therapeutics Ltd (ENLV) is between to according to relative valuation methord.
What is Enlivex Therapeutics Ltd (ENLV) fair value?
How does ENLV's valuation metrics compare to the industry average?
What is the current P/B ratio for Enlivex Therapeutics Ltd (ENLV) as of Aug 14 2025?
What is the current FCF Yield for Enlivex Therapeutics Ltd (ENLV) as of Aug 14 2025?
What is the current Forward P/E ratio for Enlivex Therapeutics Ltd (ENLV) as of Aug 14 2025?